MeiraGTx Reports Positive 3-Year Data for AAV-hAQP1 in Xerostomia, Projecting Billions in Peak Revenue

summarizeSummary

MeiraGTx announced highly positive three-year clinical data for its AAV-hAQP1 gene therapy in radiation-induced xerostomia, demonstrating sustained efficacy and safety, with the company projecting multi-billion dollar peak annual revenue potential.

check_boxKey Events

• Positive 3-Year Clinical Data

  AAV-hAQP1 gene therapy showed sustained safety and efficacy in treating radiation-induced xerostomia over three years in the Phase 1 AQUAx study.

• Sustained Efficacy Demonstrated

  Clinically meaningful improvements in Xerostomia Questionnaire (XQ) scores and normalization of Unstimulated Whole Saliva Flow Rate (UWSFR) were maintained for 36 months after a single treatment.

• Significant Commercial Opportunity

  The company estimates peak global annual revenue potential of up to $3.7 billion for AAV-hAQP1, addressing a large unmet medical need.

• Potential First-in-Class Therapy

  AAV-hAQP1 is positioned as a potential first-in-class, disease-modifying therapy for severe, lifelong radiation-induced xerostomia.

auto_awesomeAnalysis

This 8-K formalizes the highly positive three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1, a gene therapy for radiation-induced xerostomia. The data confirms the therapy's safety and remarkable durability, with clinically meaningful improvements in both patient-reported symptoms (XQ scores) and objective measures (saliva flow rate) maintained for 36 months after a single treatment. The company's projection of up to $3.7 billion in peak global annual revenue, significantly exceeding its current market capitalization, highlights the transformative commercial opportunity for this potential first-in-class, disease-modifying therapy. This de-risks a key pipeline asset and provides a strong long-term growth outlook, reinforcing investor confidence. This news was previously announced via a press release today.